Associate Sponsors

Co-sponsor

Budget 2026: Pharma dept prescribes PLI boost for bulk drug output

FY27 PLI scheme allocation rises 2.24%, aiming to add 500 MT to domestic API production

pharma medicine drugs
Sanket Koul New Delhi
2 min read Last Updated : Feb 02 2026 | 11:47 PM IST
The Department of Pharmaceuticals (DoP) plans to boost production under its production-linked incentive (PLI) schemes for bulk drugs, medical devices, and pharmaceuticals in 2026-27 (FY27), with the schemes receiving a 2.24 per cent increase in allocation this year.
 
Budget Estimates (BE) for FY27 peg the combined allocation for the three schemes at ₹2,499.84 crore, up from ₹2,444.93 crore in 2025-26 BE.
 
According to Budget documents reviewed by Business Standard, DoP aims to add 500 metric tonnes (MT) per annum of manufacturing capacity for bulk drugs in FY27, bringing total production to drugs worth ₹1,250 crore this year.
 
The scheme focuses on domestic production of critical active pharmaceutical ingredients (APIs) used in essential drugs for which there are no alternatives, reducing supply disruption risks caused by over-reliance on a single source.
 
This announcement comes days after the Centre introduced a minimum import price for APIs such as penicillin-G, amoxicillin, and 6-APA (6-aminopenicillanic acid) to counter aggressive undercutting and dumping by Chinese manufacturers.
 
The department is also targeting production of drugs worth ₹1.08 trillion in FY27 under the PLI scheme for pharmaceuticals not covered by the bulk drugs scheme. This marks an increase from the ₹90,000 crore production target last year, incentivising high-value medicines such as biopharmaceuticals, complex generics, patented drugs or drugs nearing patent expiry, autoimmune treatments, and anti-cancer drugs.
 
Under the two schemes, cumulative sales of ₹3.19 trillion have been reported by approved pharmaceutical applicants since the scheme’s inception in 2019 till September 2025, according to DoP.
 
The department also plans to commission three new medical device projects, aiming for total sales of ₹4,000 crore under the PLI scheme for domestic manufacturing of such devices.
 
 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :pharmaceutical firmsPharma sectordrugsBudget 2026

Next Story